2. Academic Validation
  3. Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo

Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo

  • Clin Cancer Res. 2021 Feb 15;27(4):1139-1149. doi: 10.1158/1078-0432.CCR-20-3139.
Eleni Anastasiadou 1 2,  Anita G Seto 3,  Xuan Beatty 3,  Melanie Hermreck 3,  Maud-Emmanuelle Gilles 1,  Dina Stroopinsky 4,  Lauren C Pinter-Brown 5,  Linda Pestano 3,  Cinzia Marchese 2,  David Avigan 4,  Pankaj Trivedi 2,  Diana M Escolar 3,  Aimee L Jackson 3,  Frank J Slack 6
Affiliations

Affiliations

  • 1 HMS Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • 2 Department of Experimental Medicine, Sapienza University of Rome, Italy.
  • 3 miRagen Therapeutics, Inc, Boulder, Colorado.
  • 4 Department of Hematology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • 5 Department of Internal Medicine, Division of Hematology/Oncology, University of California, Irvine, California.
  • 6 HMS Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. [email protected].
PMID: 33208342 DOI: 10.1158/1078-0432.CCR-20-3139
Abstract

Purpose: miRNA-155 is an oncogenic miRNA highly expressed in B-cell malignancies, particularly in the non-germinal center B-cell or activated B-cell subtype of diffuse large B-cell lymphoma (ABC-DLBCL), where it is considered a potential diagnostic and prognostic biomarker. Thus, miR-155 inhibition represents an important therapeutic strategy for B-cell lymphomas. In this study, we tested the efficacy and pharmacodynamic activity of an oligonucleotide inhibitor of miR-155, cobomarsen, in ABC-DLBCL cell lines and in corresponding xenograft mouse models. In addition, we assessed the therapeutic efficacy and safety of cobomarsen in a patient diagnosed with aggressive ABC-DLBCL.

Experimental design: Preclinical studies included the delivery of cobomarsen to highly miR-155-expressing ABC-DLBCL cell lines to assess any phenotypic changes, as well as intravenous injections of cobomarsen in NSG mice carrying ABC-DLBCL xenografts, to study tumor growth and pharmacodynamics of the compound over time. To begin to test its safety and therapeutic efficacy, a patient was recruited who underwent five cycles of cobomarsen treatment.

Results: Cobomarsen decreased cell proliferation and induced Apoptosis in ABC-DLBCL cell lines. Intravenous administration of cobomarsen in a xenograft NSG mouse model of ABC-DLBCL reduced tumor volume, triggered Apoptosis, and derepressed direct miR-155 target genes. Finally, the compound reduced and stabilized tumor growth without any toxic effects for the patient.

Conclusions: Our findings support the potential therapeutic application of cobomarsen in ABC-DLBCL and other types of lymphoma with elevated miR-155 expression.

Figures
Products